Latest PD-1 Stories
Research Provides Potential Implications for Immunotherapy in Treatment of Gynecologic Cancers IRVING, Texas, March 29, 2015 /PRNewswire/ -- Caris Life Sciences® today announced the
CALGARY, March 26, 2015 /PRNewswire/ - Oncolytics Biotech(®) Inc. ("Oncolytics") (TSX:ONC) (NASDAQ:ONCY) today announced that Dr.
SUNNYVALE, Calif., Feb. 27, 2015 /PRNewswire/ -- Pharmacyclics, Inc.
Studies Find Potentially Predictive Biomarkers May Lead to Better Patient Outcomes, Bladder Cancer Treatment Options Extend Beyond Chemotherapy Milwaukee, WI
immunoSEQ(TM) Next Generation Sequencing Assay Confirms Presence of Active Immune Response in Responders Prior to Treatment SEATTLE, Nov.
SAN DIEGO and BARCELONA, Spain, Nov.
Results Published in Cancer Epidemiology, Biomarkers & Prevention Demonstrate Utility of Caris Molecular Intelligence(TM) in Exploring Expression of Targetable Immune Proteins IRVING,
The Emergence of Keytruda--the First PD-1 Inhibitor Approved in the U.S.--is a Significant Milestone in Oncology, According to Decision Resources Group BURLINGTON, Mass., Sept.
Immune Checkpoint Inhibitors Will Hold an Impressive 85 Percent Market Share, According to Findings from Decision Resources Group BURLINGTON, Mass., June 30, 2014 /PRNewswire/ -- Decision Resources
NKTR-214 combined with anti-PD-1 or anti-CTLA-4 provides significant tumor growth inhibition in both EMT6 breast and CT26 colon tumor models SAN FRANCISCO, June 1, 2014 /PRNewswire/
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.